Abstract:Abstract Background: It is hypothesized that TLR7 agonists reprogram myeloid cells in the TME, which may lead to activation of antitumor CD8 T effector cells and subsequently tumor cell death. The orally available TLR7 agonist prodrug RO7119929 is mainly converted into its active form in the liver. Here we report preclinical data informing the clinical proof of mechanism (PoM) strategy for RO7119929, as well as confirmatory clinical data from the first-in-human, Phase I study (NCT04338685). Methods: Prior to the Phase 1 study, bulk RNA sequencing of tumor and liver tissue was performed in a RO7119929 -treated HEP55.1c mouse model and RO7119929-treated cynomolgus monkeys. Single cell and single nucleus RNA-sequencing (snRNA-seq) was also performed in RO7119929 -treated human peripheral blood mononuclear cells (PBMCs). The Phase 1 study subsequently enrolled 55 pts with advanced primary liver cancers or other solid tumors with predominant liver involvement to receive weekly RO7119929. Paired pre- and post-treatment tumor liver biopsies were assessed. Pharmacodynamic (PD) monitoring of proximal and distal TLR7-related PD markers was performed using snRNA-seq, immunohistochemistry (IHC) and flow cytometry. Results: Preclinical mouse, cynomolgus monkey as well as human derived data showed dose-dependent, TLR7 mode of action-related, immune stimulatory reprogramming of PBMCs, the TME and liver tissue via myeloid cell activation. These findings were translated into a Phase I expansion cohort to demonstrate PoM using predefined PD gating criteria. By implementing snRNA-seq of paired liver biopsies from 11 pts, clinical PoM of RO7119929 could be demonstrated on a cellular and cytokine/chemokine level. Macrophages were the predominant immune infiltrate in liver tumor tissue and showed a relative increase in numbers and a trend towards an M1-immune stimulatory phenotype reprogramming on treatment. The local induction of proximal and distal cytokines and chemokines further confirmed a general shift towards a proinflammatory TME. In addition, peripheral CD8 T cell expansion was observed in most pts analyzed. An increase in CD8 tumor-infiltrating lymphocytes (TILs) occurred in 4/9 pts (all presented with stable disease) while most pts with no TIL increase had disease progression as best response. However, a general change towards a predominant CD8 inflamed immune phenotype was not detected. There was no trend for TLR7-induced increase in PD-L1 or MHC class I expression. Conclusions: Single-agent TLR7 agonist treatment of advanced primary or metastatic liver cancers induces local inflammation of the TME by reprogramming myeloid cells. Combination therapies may be needed to increase the relocation of antitumor CD8 T effector cells to the TME and unlock the full potential of the local immune stimulatory effect. Citation Format: Carles Fabregat-Franco, Changhoon Yoo, Bruno Sangro, Camilla Qvortrup, Hyung-Don Kim, Teresa Macarulla, Mariano Ponz-Sarvisé, Chia-Chi Lin, Do-Youn Oh, Thomas Yau, Juliana Bessa, Petra C. Schwalie, Steffen Dettling, Ramona Schlenker, Natascha Riede, Elia Hall, Felix Lichtenegger, Nicole Kratochwil, Thomas Pöschinger, Zhiwen Jiang, Tianyi Jiang, Christina Godfried Sie, Audrey Yeo Te-Ying, Christina Schiff, Sabine Hoves, Michael Cannarile. RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or metastatic liver cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2342.

Abstract 4144: Characterization of immune cell phenotypes in patient derived malignant pleural effusion treated with thiostrepton

Abstract 384: SLC7A11 modulates sensitivity to the first-in-class mitochondrial peroxiredoxin 3 inhibitor thiostrepton (RSO-021) via a ferroptosis independent pathway

Abstract 4716: First-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 triggers mesenchymal-to-epithelial transition in mesothelioma

Abstract 3685: Targeting a novel cell surface serine protease TMPRSS11B for lung cancer therapy

Abstract 6518: BPM 31510: Targeting the tumor microenvironment (TME) via mitochondrial-mediated ROS production

Abstract B011: MTA-cooperative PRMT5 inhibition (BMS-986504) induces MTAP del tumor cell-intrinsic immune evasion and regulation

Abstract C077: STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment

Abstract 6642: Exploring the x-ray psoralen activated cancer therapy mechanism of action in a genetically engineered mouse model of soft tissue sarcoma

Abstract 6734: Preclinical impact of pretreatment with CRS mitigation agents on pharmacodynamic response to TAK-500, a systemically delivered CCR2-targeted STING agonist iADC

Abstract PO5-27-06: Development of TTX-MC138, a First-In-Class miRNA-10b-Targeted Therapeutic Against Metastatic Cancers of Diverse Primary Disease Origins

Abstract 2342: RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or metastatic liver cancers

Abstract CT141: A phase 1 trial of RTX-240, an allogeneic engineered red blood cell with cell -surface expression of 4-1BBL and trans-presented IL-15, in patients with advanced solid tumors

Abstract 2325: Targeting kynurenine pathway using novel IDO/TDO dual inhibitor (AT0174) to modulate tumor microenvironment in platinum resistant non-small cell lung cancer cancer: An immunometabolism compliment markers

Abstract 5171: TP-6379, an investigational TGFBR1 inhibitor, shown to remodel the tumor microenvironment and enhance anti-tumorigenic immunological responses in syngeneic mouse models of cancer

Abstract 3045: PPAR-α antagonist enhances immunotherapy and anti-angiogenic therapy to inhibit murine renal cancer

Abstract 666: ASTX295 engages p53-mediated apoptosis and an inflammatory response in patient derived mesothelioma explants

Abstract B041: Non-clinical Development of T-Plex Component TSC-203-A0201: A TCR-T Cell Therapy Directed to an HLA-A*02:01-Restricted PRAME Epitope for the Treatment of Solid Tumors

Abstract 587: Tumor treating fields induce the integrated stress response, alter the transcriptional signatures of cellular metabolism, and modulate immune-related cytokines dependent and independent of p53

Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study

Abstract 465: The preclinical characterization of TST003, a first-in-class mAb targeting gremlin-1 overexpressed by cancer-associated fibroblasts and tumor cells

Abstract 1042: Fc3TSR improves intratumoral treatment delivery by normalizing tumor vasculature and reducing interstitial fluid pressure in an orthotopic, syngeneic mouse model of epithelial ovarian cancer